Novo Nordisk's Pivot Point: From Pricing Power to Proof of Concept

Novo Nordisk faces competitive and pricing pressures despite strong oral Wegovy sales, as Eli Lilly advances and pipeline setbacks weigh on shares.

The arithmetic of obesity-drug investing has grown more complicated for Novo Nordisk. The Danish pharmaceutical group's shares closed at €40.14 on Wednesday, down 2.1 percent on the day and roughly 27 percent below the January high of €54.86 — a slide that has erased much of the enthusiasm that once surrounded the Wegovy franchise.

That erosion of confidence comes despite a business that continues to deliver on several fronts. The oral version of Wegovy has generated more than five million prescriptions since its US launch in January, capturing roughly 90 percent of the American market for oral weight-loss treatments, according to company figures. CEO Mike Doustdar pushed back against the notion that the market will become a "winner-take-all" contest with Eli Lilly, arguing that patients want a range of mechanisms and delivery formats that can accommodate multiple major players.

A Two-Pronged Competitive Squeeze

The competitive pressure, however, is becoming harder to wave away. Eli Lilly confirmed on August 7 that it will file its next-generation weight-loss candidate with the FDA, signaling a fresh challenge to Novo Nordisk's dominance. Meanwhile, Washington is tightening the screws from another direction: the company will cut list prices for Ozempic and Wegovy to $675 per month starting in January 2027, a concession to political pressure and a recognition that its pricing leverage is no longer what it once was.

Analysts see Eli Lilly positioning itself to capture a disproportionate share of the US Medicare market, and the Berenberg team is among those taking a more cautious stance. Analyst Kerry Holford downgraded the stock from "Buy" to "Hold" on August 12, trimming the Copenhagen-listed shares' price target to 305 Danish kroner from 325. Her reasoning: the upside from the oral Wegovy launch is already reflected in the share price, while Eli Lilly continues to build out its competitive advantages.

Pipeline Setbacks Complicate the Narrative

The clinical front has delivered its share of disappointments. The Phase 3 ZEUS trial of Ziltivekimab failed to meet its primary endpoint, showing no significant reduction in major cardiovascular events for patients with chronic kidney disease and atherosclerotic cardiovascular disease. The company will take a non-cash impairment charge of 6.3 billion Danish kroner on pipeline assets in the third quarter.

CagriSema, another hopeful candidate, produced weight loss of 23 percent — below the roughly 25 percent that market expectations had baked in. For a stock that once traded as a momentum favorite, the message is uncomfortable: the market now wants evidence, not promises.

The Operating Picture Holds Up

Beneath the noise, the underlying business remains resilient. Second-quarter adjusted revenue came in at 78.49 billion Danish kroner, up 7 percent at constant exchange rates, while adjusted operating profit rose 11 percent to 33.39 billion kroner. Reported operating profit, however, fell 16 percent to 27.06 billion kroner, dragged down by the impairment charge.

Management raised its full-year guidance, narrowing the expected decline in adjusted sales and operating profit at constant exchange rates to a range of 0 to minus 6 percent, an improvement from the previous forecast of minus 4 to minus 12 percent.

The company is also pressing ahead with innovation beyond pharmacology. A new partnership with Amazon Web Services will establish a "co-innovation hub" in London focused on using AI agents and cloud technology to accelerate drug discovery and clinical development. Novo Nordisk has also launched Awiqli, the first once-weekly basal insulin in the US, and continues to expand manufacturing capacity aggressively.

Buybacks and the Valuation Question

Shareholder returns remain a priority. Between August 4 and 7, the company repurchased 820,000 B-shares for 246.8 million kroner as part of a 15 billion kroner buyback program, bringing cumulative purchases to nearly 27.9 million B-shares for 7.78 billion kroner. In the first half of 2026, the company distributed 41.2 billion Danish kroner to shareholders.

The valuation debate is split. With a market capitalization of €181 billion, Novo Nordisk remains one of Europe's largest pharmaceutical companies, and some analysts argue the stock now looks inexpensive, with a price-to-earnings ratio well below the sector average. The technical picture tells a more cautious story: the shares sit 28 percent below their 52-week high, with an RSI of 41.3 reflecting lingering investor unease.

Whether a lower multiple can offset competitive fears and clinical setbacks is the central question. The answer will depend less on the current valuation than on whether Novo Nordisk can reclaim some of its pricing power — a test that will become visible in how the market reacts to the January 2027 price cuts. For now, the company finds itself in an uncomfortable transition: no longer the undisputed monopolist, but still a formidable player in a market it helped create.